DGAP-News: Epigenomics AG / Key word(s): Miscellaneous 11.06.2018 / 08:37 The issuer is solely responsible for the content of this announcement. Press release Centers for Medicare & Medicaid Services publish preliminary rate for Epigenomics’ colorectal cancer screening test Epi proColon(R) Medicare Administrative Contractors determine rate of $192 per test Berlin (Germany) and Germantown, MD (U.S.A.), […]
Category: Press Releases
11. June 2018
Epigenomics AG: Centers for Medicare & Medicaid Services publish preliminary rate for Epigenomics’ colorectal cancer screening test Epi proColon(R)
Read more
09. May 2018
Epigenomics AG announces 2018 First Quarter Financial Results
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement 09.05.2018 / 08:20 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG announces 2018 First Quarter Financial Results Berlin (Germany) and Germantown, MD (U.S.A.), May 9, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced […]
19. April 2018
Epigenomics AG: Blood test shows promise in the detection of liver cancer
DGAP-News: Epigenomics AG / Key word(s): Study results 19.04.2018 / 06:40 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG: Blood test shows promise in the detection of liver cancer – Results from two clinical studies demonstrate high sensitivity and specificity of mSEPT9 blood test – mSEPT9 test exhibited […]
16. April 2018
Original-Research: Epigenomics AG (von First Berlin Equity Research GmbH)
Original-Research: Epigenomics AG – von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Epigenomics AG Unternehmen: Epigenomics AG ISIN: DE000A11QW50 Anlass der Studie: Update Empfehlung: Buy seit: 16.04.2018 Kursziel: €7,10 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: – Analyst: Simon Scholes First Berlin Equity Research has published a research […]
16. April 2018
Original-Research: Epigenomics AG (von First Berlin Equity Research GmbH)
Original-Research: Epigenomics AG – von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Epigenomics AG Unternehmen: Epigenomics AG ISIN: DE000A11QW50 Anlass der Studie: Update Empfehlung: Buy seit: 16.04.2018 Kursziel: €7,10 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: – Analyst: Simon Scholes First Berlin Equity Research has published a research […]
23. March 2018
Epigenomics AG Reports Results for Financial Year 2017
DGAP-News: Epigenomics AG / Key word(s): Final Results 23.03.2018 / 08:20 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Reports Results for Financial Year 2017 Berlin (Germany) and Germantown, MD (U.S.A.), March 23, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), or the “Company”, today announced […]